Skip to main content
. 2015 Jul 16;59(8):4882–4888. doi: 10.1128/AAC.00440-15

TABLE 3.

Activity of WPR-6 against clinical HIV-1 isolates circulating predominantly in China

HIV-1 isolate Virus subtype Cell type Tropisma EC50 (μM)b SI50c EC90 (μM)b SI90d
XJDC6291 CRF07_BC TZM-bl CCR5 0.006 ± 0.001 12,735 0.025 ± 0.001 14,416
XJDC6291 CRF07_BC PBMCs CCR5 0.003 ± 0.001 45,933 0.103 ± 0.010 2,890
020100968 B′ TZM-bl CCR5 0.004 ± 0.002 18,021 0.016 ± 0.003 22,329
020100968 B′ PBMCs CCR5 0.002 ± 0.001 68,900 0.209 ± 0.014 1,424
020100311 B′ TZM-bl CCR5/CXCR4 0.001 ± 0.001 76,410 0.007 ± 0.001 51,484
020100311 B′ PBMCs CCR5/CXCR4 0.002 ± 0.001 68,900 0.119 ± 0.012 2,501
CYM015 CRF01_AE TZM-bl CCR5 0.001 ± 0.001 76,410 0.053 ± 0.009 6,800
CYM015 CRF01_AE PBMCs CCR5 0.006 ± 0.001 22,967 0.209 ± 0.014 1,424
CYM033 CRF01_AE TZM-bl CCR5 0.002 ± 0.001 39,386 0.014 ± 0.003 24,958
CYM033 CRF01_AE PBMCs CCR5 0.005 ± 0.001 27,560 0.302 ± 0.023 985
a

HIV-1 isolate uses CXCR4 (CXC chemokine receptor 4), CCR5 (chemokine receptor 5), or both for cell infection.

b

EC50s and EC90s were determined on the basis of the data from virus inhibition assays with fresh human PBMCs or TZM-bl cells. The experiment was performed in triplicate, and the data presented are mean values ± standard deviations from at least two independent experiments.

c

The SI is the ratio of the CC50s for PBMCs, MT-4 cells, and TZM-bl cells to the EC50s for inhibition of clinical HIV-1 isolates of different subtypes.

d

The SI is the ratio of the CC90s for PBMCs and TZM-bl cells to the EC90s for inhibition of clinical HIV-1 isolates of different subtypes.